ISIS 2503

DB16181InvestigationalGene Therapies

ISIS 2503 is under investigation in clinical trial NCT00004193 (ISIS 2503 in Treating Patients With Metastatic And/or Locally Recurrent Colorectal Cancer).

Mechanism: Pharmacologically active on GTPase HRas
Curator reviewed
Also known as: H-ras antisense oligodeoxynucleotide isis 2503
Code names: ISIS-2503

Resolves to

Compound

UNIII444I66XWHCAS149957-14-2

Targets

P01112HRAS

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with ISIS 2503, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account